文章核心观点 - 公司本季度收入为144.6亿美元,同比增长4.3% [1][2] - 每股收益为2.65美元,去年同期为2.91美元 [1][2] - 公司业绩超出市场预期,收入和每股收益分别超出预期2.96%和3.11% [2] 公司业务表现 免疫学业务 - 免疫学业务美国收入57.2亿美元,同比下降0.2% [5] - 免疫学业务国际收入12.5亿美元,同比增长15.9% [5] - 免疫学业务总收入69.7亿美元,同比增长2.3% [5] Rinvoq业务 - Rinvoq美国收入10.2亿美元,同比增长57.7% [5] - Rinvoq国际收入4.13亿美元,同比增长51.3% [5] 眼科业务 - 眼科业务总收入5.33亿美元,同比下降13.6% [5] 美学业务 - 美学业务总收入13.9亿美元,同比增长0.4% [5] 神经科学业务 - 神经科学业务总收入21.6亿美元,同比增长14.7% [5] Qulipta业务 - Qulipta总收入1.5亿美元,同比增长56.3% [5] Humira业务 - Humira收入28.1亿美元,同比下降29.9% [5] Creon业务 - Creon收入3.72亿美元,同比增长31.9% [5] Duodopa业务 - Duodopa收入1.13亿美元,同比下降3.4% [5]

文章核心观点 - 公司本季度每股收益2.65美元,超出市场预期2.57美元,但低于去年同期2.91美元[1] - 公司连续4个季度超出市场每股收益预期[2] - 公司本季度收入146.6亿美元,超出市场预期142.1亿美元,同比增长4.2%[3] - 公司股价今年以来涨幅与标普500指数基本持平[4] 公司表现 - 公司本季度每股收益2.65美元,超出市场预期2.57美元,但低于去年同期2.91美元[1] - 公司连续4个季度超出市场每股收益预期[2] - 公司本季度收入146.6亿美元,超出市场预期142.1亿美元,同比增长4.2%[3] - 公司股价今年以来涨幅与标普500指数基本持平[4] 行业表现 - 公司所属大型制药行业目前在250多个Zacks行业中排名靠后,在底部21%[10] - 研究显示,Zacks排名靠前的50%行业的表现要优于底部50%的行业2倍以上[10] - 另一家制药公司默克(Merck)预计本季度每股收益2.16美元,同比增长204.9%,收入将达159亿美元,同比增长5.7%[12]

PALM BEACH, Fla., July 25, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The fibromyalgia treatment market has witnessed positive growth trends over the past few years. There is higher disease awareness due to growth in diagnosis rates and growing awareness and concern for this serious, debilitating condition. Moreover, rising healthcare expenditure and presence of favorable reimbursement policies are also contributing to the market expansion. New drugs in development having novel mechanisms of ...

The drug company has a famously strong dividend record -- and that looks set to continue.It was great while it lasted, but AbbVie's (ABBV 1.77%) most important cash cow -- rheumatoid arthritis treatment Humira -- has been out of patent exclusivity in the U.S. since last year. That's not the only change the drugmaker experienced in the past 18 months. AbbVie also replaced its leader as CEO Richard Gonzalez stepped down; Gonzalez had been at the helm since 2013.The pharmaceutical giant delivered excellent ret ...

收购和费用 - 第二季度2024年预计收购的IPR&D和里程碑费用为9.37亿美元，对每股稀释收益均有不利影响[7] 每股收益指引 - AbbVie公司2024年调整后每股收益指引范围为10.61 - 10.81美元[8] - AbbVie公司2024年第二季度调整后每股收益指引范围为2.53 - 2.57美元[8]

文章核心观点 - 公司第二季度业绩超预期,主要得益于免Humira产品线的强劲增长 [9] - 公司上调了2024年全年调整后每股收益指引,但同时也提示了与收购相关的一次性费用 [7][34] 业务表现总结 免疫学业务 - 免疫学业务整体收入增长2.3%,其中Skyrizi和Rinvoq收入分别增长44.8%和55.8% [11] - Humira收入下降29.8%,主要受到专利到期的影响 [11] 肿瘤业务 - 肿瘤业务整体收入增长10.5%,其中Venclexta收入增长11.5% [12] - Imbruvica收入下降8.2% [12] - 新产品Elahere收入达到1.28亿美元 [12] 神经科学业务 - 神经科学业务整体收入增长14.7%,其中Botox Therapeutic、Vraylar和Ubrelvy/Qulipta收入分别增长8.7%、17.6%和17.5%/56.3% [13] 美容业务 - 美容业务整体收入增长0.5%,其中Botox Cosmetic收入增长6.4%,但Juvederm收入下降6.8% [14] 其他业务 - 眼科业务收入下降13.3%,主要受到Restasis和Alphagan/Combigan收入下滑的影响 [46] - 其他主要产品中,Creon收入增长32.1%,但Mavyret和Linzess/Constella收入分别下降4.7%和20.7% [47]

Arguably, there’s never a bad time to consider trustworthy dividend stocks. By securing passive income, you can complement any returns you generate through speculation. Also, by having dividend-paying companies in your portfolio, you stand a better chance of ending up in positive territory. These factors may become even more critical at this present juncture.Over the weekend, President Joe Biden announced that he would no longer seek reelection. Instead, he will focus on finishing out his term. This massive ...

The second-quarter 2024 reporting cycle of the Medical sector is about to pick up pace this week. The sector mainly comprises pharma/biotech and medical device companies.The earnings season for the drug and biotech sector kicked off last week when bellwether Johnson & Johnson reported strong second-quarter results, beating estimates for earnings and sales.Swiss pharma giant Novartis AG also reported better-than-expected second-quarter results. Consequently, Novartis increased its operating income growth gui ...

AbbVie (ABBV) will report second-quarter earnings on Jul 25, before the opening bell. The Zacks Consensus Estimate for sales and earnings is pegged at $14.05 billion and $2.56 per share, respectively.Though the company’s earnings estimates have declined from $11.27 per share to $10.81 for 2024 in the past 60 days, they have increased from $12.08 to $12.13 for 2025 during the same period. Image Source: Zacks Investment ResearchEarnings Surprise HistoryAbbVie’s performance has been impressive, with its earnin ...

The big pharma company's top drug is losing ground, but its dividend keeps rising.Shares of Big Pharma company AbbVie (ABBV 0.33%) inched higher recently in response to positive news from a Wall Street investment bank. BMO Capital analyst Evan Seigerman raised his price target on the stock from $180 to $214 per share on Friday, July 19.Bullishness for AbbVie might seem foolhardy to the casual observer. The company's lead drug, Humira, finally lost patent-protected exclusivity in the U.S. market last year, a ...